Patents by Inventor James B. Streisand

James B. Streisand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of TGF-Beta Antagonists to Treat Infants at Risk of Developing Bronchopulmonary Dysplasia
    Publication number: 20170233464
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Application
    Filed: November 28, 2016
    Publication date: August 17, 2017
    Applicants: GENZYME CORPORATION, THE GENERAL HOSPITAL CORPORATION
    Inventors: James B. Streisand, Jesse D. Roberts, JR.
  • USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA
    Publication number: 20140199399
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Application
    Filed: December 23, 2013
    Publication date: July 17, 2014
    Applicants: The General Hospital Corporation, Genzyme Corporation
    Inventors: James B. STREISAND, Jesse D. ROBERTS, JR.
  • Use of TGF-? antagonists to treat infants at risk of developing bronchopulmonary dysplasia
    Patent number: 8642034
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Grant
    Filed: October 3, 2007
    Date of Patent: February 4, 2014
    Assignee: Genzyme Corporation
    Inventors: James B. Streisand, Jesse D. Roberts, Jr.
  • USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA
    Publication number: 20100008911
    Abstract: The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-? antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-? antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
    Type: Application
    Filed: October 3, 2007
    Publication date: January 14, 2010
    Inventors: James B. Streisand, Jesse D. Roberts, JR.